Pliant Therapeutics Inc. (9PT)
XFRA 
Summary
9PT Chart
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration
Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional base, the March 2026 poison pill expiration signals a potential liquidation or premium buyout. PLRX's cash burn has been slashed, extending runway to 2028, but continued independent operation is untenable; forced liquidation or cash privatization is highly likely in my opinion.
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant Therapeutics Inc. (9PT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pliant Therapeutics Inc. ever had a stock split?
Pliant Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bernard Coulie CEO | XFRA Exchange | 729139105 CUSIP |
| US Country | 49 Employees | - Last Dividend | - Last Split | 3 Jun 2020 IPO Date |
Overview
Pliant Therapeutics, Inc. is a pioneering clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of fibrosis and associated diseases. Founded in 2015, the company has quickly positioned itself at the forefront of fibrotic disease treatment research, operating from its headquarters in South San Francisco, California. With a robust pipeline of investigational drugs aimed at tackling fibrosis from various angles, Pliant Therapeutics is leading the charge against this complex set of diseases with its cutting-edge scientific approaches and a deep commitment to patient care.
Products and Services
Pliant Therapeutics' diverse portfolio of therapeutic candidates reflects its mission to address fibrosis through novel treatments. Below is an overview of their key products in development:
- Bexotegrast: This oral, small-molecule therapy acts as a dual selective inhibitor of avß6 and avß1 integrins. Currently undergoing a phase 2b trial for idiopathic pulmonary fibrosis, bexotegrast represents a significant breakthrough in treating this challenging and progressive disease. Additionally, it is in a phase 2a trial for primary sclerosing cholangitis, underscoring its potential versatility in treating various fibrotic conditions.
- PLN-1474: Another promising candidate is PLN-1474, an oral, small-molecule selective inhibitor specifically targeting avß1 integrins. Its development is geared towards tackling liver fibrosis associated with nonalcoholic steatohepatitis (NASH), a condition with a high unmet medical need. By focusing on a key pathway involved in the fibrotic process, PLN-1474 has the potential to offer a novel treatment option for patients with NASH.
- PLN-101095: This compound is designed as a dual inhibitor of integrins avß8 and avß1, with a focus on the treatment of solid tumors. By targeting these specific integrins, PLN-101095 aims to disrupt the fibrotic microenvironment tumors often rely on for growth and survival, offering a new avenue for cancer treatment.
- PLN-101325: This investigational drug is under development for the treatment of muscular dystrophies, a group of diseases characterized by progressive muscle weakness and degeneration. Given that fibrosis can exacerbate the progression of muscular dystrophies, targeting the fibrotic component with PLN-101325 could significantly benefit patients suffering from these conditions.
